Trial Information

Summary: Diffuse Large B-Cell Lymphoma (DLBCL) - Adults

People with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) are asked to participate in a research study involving experimental drug/ therapy being conducted by North Shore University Hospital. A Phase 1b Study of SGN-40 (anti-huCD40 mAb) in Combination with Rituximab and Gemcitabine for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Adults

You may be eligible to participate in this study if you:

• Are at least 18 years of age
• Have been diagnosed with DLBCL

You may not participate in this study if you:

• Have a history (within 6 months) of stroke, unstable angina, heart attack, or other cardiac condition
• Have received allogeneic stem cell transplant
• Had major surgery within 4 weeks
• Have any active systemic viral, bacterial, or fungal infection requiring intravenous anti-infectives within 4 weeks
• Have HIV, hepatitis B or hepatitis C infection
• Have a history of central nervous system (CNS) lymphoma
• Have dementia or altered mental status or any serious underlying medical condition or psychiatric illness
• Are pregnant, breastfeeding, or intend to become pregnant during the study

If you would like to learn more about participating in this study, please send an e-mail message using the form below.